Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | SCN1A | P35498 | 7/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | MST1R | Q04912 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | ROS1 | P08922 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391902 | 0.82 | MET (0.69) | METJAK2SRCKDRKIT | |
| SCHEMBL488617 | 0.71 | MET (0.69) | METJAK2ALK | |
| SCHEMBL30453715 | 0.71 | MET (0.69) | METJAK2ALK | |
| SCHEMBL15779201 | 0.65 | MET (0.88) | METJAK2SRCKDRKIT | |
| SCHEMBL31521440 | 0.64 | ALKBH1 (0.40) | METSRCKDRKITFGFR2 | |
| SCHEMBL9967747 | 0.63 | GABRA1 (0.44) | — | |
| SCHEMBL3120131 | 0.62 | MET (1.00) | METJAK2SRCKDRKIT | |
| SCHEMBL29529122 | 0.62 | MET (1.00) | METJAK2SRCKDRKIT | |
| SCHEMBL488751 | 0.62 | MET (1.00) | METJAK2SRCKDRKIT | |
| SCHEMBL15133818 | 0.62 | MET (1.00) | METJAK2SRCKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885SCN1A 1683/4885SCN5A 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.